TY - JOUR
T1 - Front-Line Treatment in Younger Patients With Multiple Myeloma
AU - Rajkumar, S. Vincent
AU - Sonneveld, Pieter
N1 - Funding Information:
S.V.R. is supported in part by Grants No. CA62242 and CA107476 from the National Cancer Institute, Bethesda, MD. P.S. is supported in part by grants from the Dutch Cancer Foundation CKTO.
PY - 2009/4
Y1 - 2009/4
N2 - The treatment of newly diagnosed myeloma has evolved rapidly. The choice of initial therapy depends on eligibility for stem cell transplantation, as well as baseline risk factors. Eligibility for transplantation is important since the choice of initial therapy is primarily melphalan-based in patients who are not candidates for transplant, while melphalan-containing regimens are avoided as induction therapy in transplant candidates. An assessment of risk based on independent prognostic markers is important mainly for prognosis but may have some value in choice of initial therapy. For example, bortezomib-based regimens may have particular value in patients with certain high-risk features. This review discusses the current status of front-line therapy in younger patients with myeloma who are candidates for stem cell transplantation.
AB - The treatment of newly diagnosed myeloma has evolved rapidly. The choice of initial therapy depends on eligibility for stem cell transplantation, as well as baseline risk factors. Eligibility for transplantation is important since the choice of initial therapy is primarily melphalan-based in patients who are not candidates for transplant, while melphalan-containing regimens are avoided as induction therapy in transplant candidates. An assessment of risk based on independent prognostic markers is important mainly for prognosis but may have some value in choice of initial therapy. For example, bortezomib-based regimens may have particular value in patients with certain high-risk features. This review discusses the current status of front-line therapy in younger patients with myeloma who are candidates for stem cell transplantation.
UR - http://www.scopus.com/inward/record.url?scp=64749097025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64749097025&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2009.02.005
DO - 10.1053/j.seminhematol.2009.02.005
M3 - Article
C2 - 19389495
AN - SCOPUS:64749097025
SN - 0037-1963
VL - 46
SP - 118
EP - 126
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - 2
ER -